TY - JOUR
T1 - Lipid management in patients with endocrine disorders
T2 - An endocrine society clinical practice guideline
AU - Newman, Connie B.
AU - Blaha, Michael J.
AU - Boord, Jeffrey B.
AU - Cariou, Bertrand
AU - Chait, Alan
AU - Fein, Henry G.
AU - Ginsberg, Henry N.
AU - Goldberg, Ira J.
AU - Hassan Murad, M.
AU - Subramanian, Savitha
AU - Tannock, Lisa R.
N1 - Publisher Copyright:
© The Author(s) 2020.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Objective: This guideline will provide the practicing endocrinologist with an approach to the assessment and treatment of dyslipidemia in patients with endocrine diseases, with the objective of preventing cardiovascular (CV) events and triglyceride-induced pancreatitis. The guideline reviews data on dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) risk in patients with endocrine disorders and discusses the evidence for the correction of dyslipidemia by treatment of the endocrine disease. The guideline also addresses whether treatment of the endocrine disease reduces ASCVD risk. Conclusion: This guideline focuses on lipid and lipoprotein abnormalities associated with endocrine diseases, including diabetes mellitus, and whether treatment of the endocrine disorder improves not only the lipid abnormalities, but also CV outcomes. Based on the available evidence, recommendations are made for the assessment and management of dyslipidemia in patients with endocrine diseases.
AB - Objective: This guideline will provide the practicing endocrinologist with an approach to the assessment and treatment of dyslipidemia in patients with endocrine diseases, with the objective of preventing cardiovascular (CV) events and triglyceride-induced pancreatitis. The guideline reviews data on dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) risk in patients with endocrine disorders and discusses the evidence for the correction of dyslipidemia by treatment of the endocrine disease. The guideline also addresses whether treatment of the endocrine disease reduces ASCVD risk. Conclusion: This guideline focuses on lipid and lipoprotein abnormalities associated with endocrine diseases, including diabetes mellitus, and whether treatment of the endocrine disorder improves not only the lipid abnormalities, but also CV outcomes. Based on the available evidence, recommendations are made for the assessment and management of dyslipidemia in patients with endocrine diseases.
KW - Cardiovascular disease
KW - Diabetes
KW - Dyslipidemia
KW - Endocrine diseases
KW - Lipids
KW - Triglycerides
UR - http://www.scopus.com/inward/record.url?scp=85094933168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094933168&partnerID=8YFLogxK
U2 - 10.1210/clinem/dgaa674
DO - 10.1210/clinem/dgaa674
M3 - Review article
C2 - 32951056
AN - SCOPUS:85094933168
SN - 0021-972X
VL - 105
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 12
ER -
